KYKOF Stock - Kyowa Kirin Co., Ltd.
Unlock GoAI Insights for KYKOF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $495.56B | $442.23B | $398.37B | $352.25B | $318.35B |
| Gross Profit | $362.95B | $331.03B | $311.46B | $264.40B | $237.91B |
| Gross Margin | 73.2% | 74.9% | 78.2% | 75.1% | 74.7% |
| Operating Income | $91.87B | $86.44B | $82.37B | $61.17B | $58.99B |
| Net Income | $59.87B | $81.19B | $53.57B | $52.35B | $47.03B |
| Net Margin | 12.1% | 18.4% | 13.4% | 14.9% | 14.8% |
| EPS | $113.06 | $151.01 | $99.68 | $97.43 | $87.56 |
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
Visit WebsiteEarnings History & Surprises
KYKOFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 4, 2026 | — | — | — | — |
Q4 2025 | Oct 30, 2025 | $0.23 | $0.00 | -99.4% | ✗ MISS |
Q3 2025 | Jul 31, 2025 | $0.22 | $0.13 | -39.4% | ✗ MISS |
Q2 2025 | May 5, 2025 | $0.15 | $0.08 | -45.0% | ✗ MISS |
Q1 2025 | Feb 5, 2025 | $0.00 | $0.05 | +3638.8% | ✓ BEAT |
Q4 2024 | Oct 31, 2024 | $0.23 | $0.23 | -3.6% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $0.19 | $0.30 | +55.5% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $0.21 | $0.17 | -18.3% | ✗ MISS |
Q1 2024 | Feb 7, 2024 | $0.51 | $0.35 | -32.3% | ✗ MISS |
Q3 2023 | Sep 30, 2023 | $0.41 | $0.40 | -3.1% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $0.18 | $0.11 | -36.7% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $0.21 | $0.18 | -15.7% | ✗ MISS |
Q1 2023 | Feb 7, 2023 | $0.21 | $0.06 | -70.1% | ✗ MISS |
Q4 2022 | Nov 4, 2022 | $0.18 | $0.18 | -2.9% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $0.19 | $0.26 | +35.8% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $0.16 | $0.23 | +41.4% | ✓ BEAT |
Q1 2022 | Feb 7, 2022 | $0.18 | $0.31 | +71.5% | ✓ BEAT |
Q4 2021 | Nov 1, 2021 | $0.23 | $0.13 | -45.0% | ✗ MISS |
Q3 2021 | Aug 3, 2021 | $0.23 | $0.21 | -10.6% | ✗ MISS |
Latest News
Kura Oncology and Kyowa Kirin Report KOMZIFTI Data In AML, Showing High Remission Rates In Newly Diagnosed NPM1-m Patients, Strong Responses In Relapsed/Refractory NPM1-m And KMT2A-r AML, Favorable Safety Profile With Venetoclax/Azacitidine Triplet And Ongoing Registrational Trials Across Multiple Front-Line And R/R AML Subtypes
📈 PositiveKura Oncology And Kyowa Kirin Announce NCCN Inclusion Of Newly FDA-Approved KOMZIFTI As Recommended Treatment For Relapsed/Refractory AML With NPM1 Mutation
📈 PositiveUltragenyx Pharmaceutical Announces $400M Sale Of Additional 25% Royalty Interest From Kyowa Kirin On Future Sales Of Crysvita In U.S., Canada To OMERS
📈 PositiveKura Oncology Gets $30M Milestone Payment Under Partnership Agreement With Kyowa Kirin In Dosing First Participant In Second KOMET-017 Phase 3 Registration Trials Of Ziftomenib
📈 PositiveKura Oncology Receives $30M Development Milestone Payment Under Its Collaboration With Kyowa Kirin From Dosing First Patient In KOMET-017 Phase 3 Trial
📈 PositiveKura Oncology And Kyowa Kirin Announce Dosing Of First Patient In Cohort Of KOMET-007 Clinical Trial
➖ NeutralKura Oncology And Kyowa Kirin Dose First Patient In Phase 3 KOMET-017 Trial Of Ziftomenib For Frontline Acute Myeloid Leukemia
📈 PositiveAmgen And Kyowa Kirin Highlight Rocatinlimab Long-Term Durability Of Response In Adults From Global Phase 3 ASCEND Atopic Dermatitis Program
📈 PositiveFrequently Asked Questions about KYKOF
What is KYKOF's current stock price?
What is the analyst price target for KYKOF?
What sector is Kyowa Kirin Co., Ltd. in?
What is KYKOF's market cap?
Does KYKOF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to KYKOF for comparison